Hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia

Takaharu Matsuyama, Koji Kato, Ryoji Hanada, Keisei Kawa, Jun Okamura, Masahiro Tsuchida, Hisato Kigasawa, Arata Watanabe, Kazuko Hamamoto, Tooru Kudoh, Kimihiko Sano, Mutsuro Ohira

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

A multicenter comparative study was carried out to investigate the efficacy and safety of hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia. One hundred twenty three patients at a variety of remission stages were eligible for study participation. Eighty-nine were transplanted with allogeneic grafts and 34 patients with autologous grafts (23 cases with bone marrow and 11 cases with peripheral blood stem cells). Conditioning regimens used were as follows: (A) melphalan and busulfan for 40 patients, (B) melphalan, busulfan and TBI for 44 patients, (C) other regimens for 39 patients. To accelerate engraftment G-CSF (lenograstim) was administered as a 1-hour or 24-hour drip infusion daily at 5 micrograms/kg from day 5 until hematological recovery. The five year disease free survival (DFS) was 63% for 42 patients at CR 1, 41% for 41 patients at CR 2 and 33% for 40 patients at other stages. There was no significant difference in the DFS between allogeneic-transplantation and autologous-transplantation in all disease stages. In patients at remission stage for CR 1 and CR 2, the 5-year DFS by conditioning regimen was 63% for regimen (A), 54% for regimen (B) and 54% for regimens with melphalan and TBI. There was no significant difference in the DFS between the groups. Serious complications such as renal failure were observed in 11%, veno-occlusive disease in 9%, and interstitial pneumonia in 9%. The most dominating cause of death was relapse in the disease (48% of deaths) which was most commonly observed in autologous transplantation. Contrary to that, treatment related toxic death was the most frequent cause of deaths in allogeneic-transplantation.

元の言語英語
ページ(範囲)527-537
ページ数11
ジャーナル[Rinshō ketsueki] The Japanese journal of clinical hematology
43
発行部数7
出版物ステータス出版済み - 1 1 2002

Fingerprint

Transplantation Conditioning
Melphalan
Hematopoietic Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
Disease-Free Survival
Busulfan
Autologous Transplantation
Homologous Transplantation
Cause of Death
Transplants
Poisons
Interstitial Lung Diseases
Granulocyte Colony-Stimulating Factor
Intravenous Infusions
Multicenter Studies
Renal Insufficiency

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

Hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia. / Matsuyama, Takaharu; Kato, Koji; Hanada, Ryoji; Kawa, Keisei; Okamura, Jun; Tsuchida, Masahiro; Kigasawa, Hisato; Watanabe, Arata; Hamamoto, Kazuko; Kudoh, Tooru; Sano, Kimihiko; Ohira, Mutsuro.

:: [Rinshō ketsueki] The Japanese journal of clinical hematology, 巻 43, 番号 7, 01.01.2002, p. 527-537.

研究成果: ジャーナルへの寄稿記事

Matsuyama, T, Kato, K, Hanada, R, Kawa, K, Okamura, J, Tsuchida, M, Kigasawa, H, Watanabe, A, Hamamoto, K, Kudoh, T, Sano, K & Ohira, M 2002, 'Hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia', [Rinshō ketsueki] The Japanese journal of clinical hematology, 巻. 43, 番号 7, pp. 527-537.
Matsuyama, Takaharu ; Kato, Koji ; Hanada, Ryoji ; Kawa, Keisei ; Okamura, Jun ; Tsuchida, Masahiro ; Kigasawa, Hisato ; Watanabe, Arata ; Hamamoto, Kazuko ; Kudoh, Tooru ; Sano, Kimihiko ; Ohira, Mutsuro. / Hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia. :: [Rinshō ketsueki] The Japanese journal of clinical hematology. 2002 ; 巻 43, 番号 7. pp. 527-537.
@article{07f7d29602ed4eccb7da512031f26f01,
title = "Hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia",
abstract = "A multicenter comparative study was carried out to investigate the efficacy and safety of hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia. One hundred twenty three patients at a variety of remission stages were eligible for study participation. Eighty-nine were transplanted with allogeneic grafts and 34 patients with autologous grafts (23 cases with bone marrow and 11 cases with peripheral blood stem cells). Conditioning regimens used were as follows: (A) melphalan and busulfan for 40 patients, (B) melphalan, busulfan and TBI for 44 patients, (C) other regimens for 39 patients. To accelerate engraftment G-CSF (lenograstim) was administered as a 1-hour or 24-hour drip infusion daily at 5 micrograms/kg from day 5 until hematological recovery. The five year disease free survival (DFS) was 63{\%} for 42 patients at CR 1, 41{\%} for 41 patients at CR 2 and 33{\%} for 40 patients at other stages. There was no significant difference in the DFS between allogeneic-transplantation and autologous-transplantation in all disease stages. In patients at remission stage for CR 1 and CR 2, the 5-year DFS by conditioning regimen was 63{\%} for regimen (A), 54{\%} for regimen (B) and 54{\%} for regimens with melphalan and TBI. There was no significant difference in the DFS between the groups. Serious complications such as renal failure were observed in 11{\%}, veno-occlusive disease in 9{\%}, and interstitial pneumonia in 9{\%}. The most dominating cause of death was relapse in the disease (48{\%} of deaths) which was most commonly observed in autologous transplantation. Contrary to that, treatment related toxic death was the most frequent cause of deaths in allogeneic-transplantation.",
author = "Takaharu Matsuyama and Koji Kato and Ryoji Hanada and Keisei Kawa and Jun Okamura and Masahiro Tsuchida and Hisato Kigasawa and Arata Watanabe and Kazuko Hamamoto and Tooru Kudoh and Kimihiko Sano and Mutsuro Ohira",
year = "2002",
month = "1",
day = "1",
language = "English",
volume = "43",
pages = "527--537",
journal = "[Rinsho ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "7",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia

AU - Matsuyama, Takaharu

AU - Kato, Koji

AU - Hanada, Ryoji

AU - Kawa, Keisei

AU - Okamura, Jun

AU - Tsuchida, Masahiro

AU - Kigasawa, Hisato

AU - Watanabe, Arata

AU - Hamamoto, Kazuko

AU - Kudoh, Tooru

AU - Sano, Kimihiko

AU - Ohira, Mutsuro

PY - 2002/1/1

Y1 - 2002/1/1

N2 - A multicenter comparative study was carried out to investigate the efficacy and safety of hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia. One hundred twenty three patients at a variety of remission stages were eligible for study participation. Eighty-nine were transplanted with allogeneic grafts and 34 patients with autologous grafts (23 cases with bone marrow and 11 cases with peripheral blood stem cells). Conditioning regimens used were as follows: (A) melphalan and busulfan for 40 patients, (B) melphalan, busulfan and TBI for 44 patients, (C) other regimens for 39 patients. To accelerate engraftment G-CSF (lenograstim) was administered as a 1-hour or 24-hour drip infusion daily at 5 micrograms/kg from day 5 until hematological recovery. The five year disease free survival (DFS) was 63% for 42 patients at CR 1, 41% for 41 patients at CR 2 and 33% for 40 patients at other stages. There was no significant difference in the DFS between allogeneic-transplantation and autologous-transplantation in all disease stages. In patients at remission stage for CR 1 and CR 2, the 5-year DFS by conditioning regimen was 63% for regimen (A), 54% for regimen (B) and 54% for regimens with melphalan and TBI. There was no significant difference in the DFS between the groups. Serious complications such as renal failure were observed in 11%, veno-occlusive disease in 9%, and interstitial pneumonia in 9%. The most dominating cause of death was relapse in the disease (48% of deaths) which was most commonly observed in autologous transplantation. Contrary to that, treatment related toxic death was the most frequent cause of deaths in allogeneic-transplantation.

AB - A multicenter comparative study was carried out to investigate the efficacy and safety of hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia. One hundred twenty three patients at a variety of remission stages were eligible for study participation. Eighty-nine were transplanted with allogeneic grafts and 34 patients with autologous grafts (23 cases with bone marrow and 11 cases with peripheral blood stem cells). Conditioning regimens used were as follows: (A) melphalan and busulfan for 40 patients, (B) melphalan, busulfan and TBI for 44 patients, (C) other regimens for 39 patients. To accelerate engraftment G-CSF (lenograstim) was administered as a 1-hour or 24-hour drip infusion daily at 5 micrograms/kg from day 5 until hematological recovery. The five year disease free survival (DFS) was 63% for 42 patients at CR 1, 41% for 41 patients at CR 2 and 33% for 40 patients at other stages. There was no significant difference in the DFS between allogeneic-transplantation and autologous-transplantation in all disease stages. In patients at remission stage for CR 1 and CR 2, the 5-year DFS by conditioning regimen was 63% for regimen (A), 54% for regimen (B) and 54% for regimens with melphalan and TBI. There was no significant difference in the DFS between the groups. Serious complications such as renal failure were observed in 11%, veno-occlusive disease in 9%, and interstitial pneumonia in 9%. The most dominating cause of death was relapse in the disease (48% of deaths) which was most commonly observed in autologous transplantation. Contrary to that, treatment related toxic death was the most frequent cause of deaths in allogeneic-transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0036651257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036651257&partnerID=8YFLogxK

M3 - Article

C2 - 12229121

AN - SCOPUS:0036651257

VL - 43

SP - 527

EP - 537

JO - [Rinsho ketsueki] The Japanese journal of clinical hematology

JF - [Rinsho ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 7

ER -